Evidence map›Paper›PMID 39990871›Full record

ArticleFrontiers in molecular biosciences2025

Defining the high-risk category of patients with cutaneous melanoma: a practical tool based on prognostic modeling.

Oleksandr Dudin, Ozar Mintser, Vitalii Gurianov, Nazarii Kobyliak, Denys Kozakov, Sofiia Livshun, Oksana Sulaieva

Abstract read
In one paragraph

Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Oleksandr DudinPathology Department, Medical Laboratory CSD, Kyiv, Ukraine.
Ozar MintserDepartment of Fundamental Disciplines and Informatics, Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine.
Vitalii GurianovEndocrinology Department, Bogomolets National Medical University, Kyiv, Ukraine.
Nazarii KobyliakPathology Department, Medical Laboratory CSD, Kyiv, Ukraine.
Denys KozakovPathology Department, Medical Laboratory CSD, Kyiv, Ukraine.
Sofiia LivshunPathology Department, Medical Laboratory CSD, Kyiv, Ukraine.
Oksana SulaievaPathology Department, Medical Laboratory CSD, Kyiv, Ukraine.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Although most cutaneous melanoma (CM) in its early stages is treatable, the risk of recurrence remains high and there is a particular ambiguity on patients prognosis. This drives to identification of prognostic biomarkers for predicting CM recurrence to guide appropriate treatment in patients with localized melanoma. Aim: This study aimed to develop a prognostic model for assessing the risk of recurrence in patients with CM, enabling prompt prognosis-driven further clinical decision-making for high-risk patients. Materials and methods: This case-control study included 172 patients with CM recurrence (high-risk group) and 30 patients with stable remission (low-risk group) 3 years after primary diagnosis. The impact of sex, age at diagnosis, anatomical site, histological characteristics (the histological type, pathological stage, ulceration; the depth of invasion, mitotic rate, lymphovascular invasion, neurotropism, association with a nevus, tumor-infiltrating lymphocyte density, tumor regression and Results: Five independent variables, including nodal status, a high mitotic rate, Breslow thickness, lymphovascular invasion, perineural invasion and regression features were identified as the most significant. A 5-factor logistic regression model was developed to assess the risk of melanoma recurrence. The sensitivity and specificity of the model were 86.1% and 72.7%, respectively. Conclusion: The developed model, which relies on routine histological features, allows the identification of individuals at high risk of CM recurrence to tailor their further management.

Indexed as

BRAF mutationscutaneous melanomahistological subtypeprognostic modelrecurrence

Identifiers

PMID39990871
PMCPMC11842245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.